BOULDER, Colo., April 20, 2005 (PRIMEZONE) -- Following the recent announcement of its intent to merge with OnSource Corporation ("OnSource") (OTCBB:OSCE), Osmotics Pharma, Inc. (OPI) has engaged The Investor Relations Group, Inc. (IRG), based in New York City, to serve as its financial relations and corporate communications agency of record.
IRG will strive to increase investor awareness of OPI within the U.S. market by individually and personally introducing OPI and its management to pre-qualified investment professionals. By providing an extensive array of public relations services, including obtaining media placements in television, radio, magazine, newspaper and trade media outlets, IRG will also focus on increasing the public awareness of OPI and its prescription product candidates under development for the treatment of dermatological disorders, antibiotic-resistant strains of bacteria and certain cancers.
In the future, U.S. investor and media inquiries relating to OPI can be directed to The Investor Relations Group, New York, N.Y., Telephone: 212.825.3210, Fax: 212.825.3229.
About Osmotics Pharma, Inc.
OPI is an emerging specialty pharmaceutical company developing prescription products for the treatment of various dermatological disorders, antibiotic-resistant strains of bacteria and certain cancers. OPI has the exclusive worldwide rights covering technologies developed by the University of California and Brigham Young University. Applications of these technologies are currently being tested by some of the leading research institutions in the world. All of OPI's products are in the development stage and subject to approval by the United States Food and Drug Administration. OPI has filed its first application with the FDA on form 510(k) seeking marketing clearance for Epiceram, a topical barrier repair cream for treatment of atopic dermatitis, radiation dermatitis and several other indications.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, the following: the ability of OnSource to sell approximately $2.0 million in Debentures, the ability of OnSource to raise additional capital in order to finance its planned pharmaceutical activities, OPI receiving the necessary approvals for its products from the FDA, successful clinical trials of OPI's planned products, the ability of OPI to commercialize its planned products, market acceptance of OPI's planned products, and OPI's ability to successfully compete in the marketplace. Although management believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the forward-looking statements will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements, the inclusion of such information should not be regarded as a representation by the company or any other person that the objectives and plans of the company will be achieved. For further information, please see the company's filings with the SEC, including its Forms 10-KSB, 10-QSB and 8-K. The company assumes no obligation to update it forward-looking statements to reflect actual results or changes in factors affecting such forward-looking statements.